OpenAI’s applications chief Fidji Simo steps back to part-time advisory role amid chronic illness

Fidji Simo, the executive OpenAI hired to turn its research breakthroughs into actual products people use, is stepping down from her full-time role to focus on recovering from a chronic illness. She’ll stay on in a part-time advisory capacity, but the day-to-day leadership of OpenAI’s applications division is effectively changing hands.

What happened and why it matters

Simo’s departure from full-time duties stems from Postural Orthostatic Tachycardia Syndrome, or POTS, a neurological condition that affects blood flow and can cause debilitating fatigue, dizziness, and cognitive difficulties. She announced a medical leave in April 2026 after what she described as a relapse over the preceding month.

Her trajectory at OpenAI was steep and deliberate. She first joined the company’s board in March 2024, then assumed the newly created role of CEO of Applications in August 2025. Before OpenAI, Simo spent a decade at Meta (formerly Facebook) and then served as CEO of Instacart from 2021 to 2025.

Under her watch, OpenAI was attempting to shift its center of gravity from pure research toward scaling consumer and enterprise applications, during a period when the organization was reportedly burning through roughly $5 billion in annual losses.

What this means for investors

Simo co-founded ChronicleBio, an organization focused on neuroimmune disorder research, linking her personal health journey directly to her professional work. That dual role as both patient and advocate had given her a unique perspective on AI’s potential in healthcare applications.

OpenAI has not publicly named a full-time replacement for Simo’s applications role. In a company already navigating complex governance challenges, including its ongoing transition from a nonprofit structure, an extended leadership gap in product operations would be a yellow flag for anyone modeling OpenAI’s competitive trajectory against the broader AI ecosystem.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.